Table 1. Distribution of SUA levels and cardio-renal-related phenotypes.
| Phenotypea | All | Arizona | Dakotas | Oklahoma |
|---|---|---|---|---|
| N (% male) | 3604 (40) | 1215 (38) | 1186 (41) | 1203 (42) |
| Serum uric acid (mg/dl) | 5.14 (1.5) | 4.87 (1.5) | 5.34 (1.5) | 5.22 (1.5) |
| Age (years) | 39.96 (17.03) | 37.21 (16.0) | 39.04 (17.1) | 43.65 (17.3) |
| eGFR (ml/(min/1.73 m2))b | 99.98 (28.0) | 111.42 (31.4) | 95.61 (24.6) | 92.78 (23.5) |
| UACR (mg/g)c | 46.47 (180.5) | 61.33 (219.4) | 38.84 (151.9) | 39.29 (162.1) |
| BMI (kg/m2)d | 32.14 (7.6) | 35.13 (8.2) | 30.17 (6.8) | 31.15 (6.9) |
| Waist circumference (cm) | 104.36 (18.1) | 111.54 (18.6) | 99.47 (17.0) | 101.95 (16.3) |
| Body fat (%) | 37.32 (10.2) | 41.43 (9.7) | 34.21 (10.0) | 36.29 (9.4) |
| Systolic blood pressure (mm Hg) | 122.39 (16.5) | 120.80 (16.5) | 119.87 (15.3) | 126.53 (16.9) |
| Diastolic blood pressure (mm Hg) | 76.19 (11.1) | 76.52 (11.3) | 75.22 (10.5) | 76.84 (11.5) |
| Total cholesterol (mg/dl) | 180.04 (34.8) | 173.86 (32.4) | 180.95 (35.6) | 185.37 (35.5) |
| High-density lipoprotein cholesterol (mg/dl) | 50.59 (14.2) | 48.43 (13.7) | 50.62 (13.5) | 52.77 (14.9) |
| Triglycerides (mg/dl) | 158.96 (93.4) | 162.28 (93.6) | 150.62 (92.4) | 163.80 (93.8) |
| Hypertensive (%) | 31.6 | 33.9 | 23.7 | 37.3 |
| Diabetic (%) | 22.7 | 32.9 | 14.3 | 20.5 |
| Medication use (yes %) | ||||
| Aspirin | 12.9 | 11.5 | 15.7 | 12.1 |
| Sulfonyureas | 10 | 14.7 | 9.9 | 5.3 |
| Metformin | 7.9 | 12.1 | 5.4 | 6.1 |
| ACE inhibitors | 14.5 | 16.6 | 11.7 | 15.3 |
| Beta blockers | 4.0 | 3.5 | 4.0 | 4.4 |
| Calcium channel blockers | 5.8 | 6.3 | 4.5 | 6.6 |
| Hydrochlorothiazide | 7.2 | 5.9 | 5.7 | 10.1 |
a
Mean (standard deviation).
b
Estimated glomerular filtration rate.
c
Urinary albumin–creatinine ratio.
d
Body mass index.